Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,440 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD133 and epithelial cell adhesion molecule expressions in the cholangiocarcinoma component are prognostic factors for combined hepatocellular cholangiocarcinoma.
Wakizaka K, Yokoo H, Kamiyama T, Kakisaka T, Ohira M, Tani M, Kato K, Fujii Y, Sugiyama K, Nagatsu A, Shimada S, Orimo T, Kamachi H, Matsuoka R, Taketomi A. Wakizaka K, et al. Among authors: fujii y. Hepatol Res. 2020 Feb;50(2):258-267. doi: 10.1111/hepr.13443. Epub 2019 Dec 18. Hepatol Res. 2020. PMID: 31661725 Free article.
Early administration of amatuximab, a chimeric high-affinity anti-mesothelin monoclonal antibody, suppresses liver metastasis of mesothelin-expressing pancreatic cancer cells and enhances gemcitabine sensitivity in a xenograft mouse model.
Fujii Y, Kamachi H, Matsuzawa F, Mizukami T, Kobayashi N, Fukai M, Taketomi A. Fujii Y, et al. Invest New Drugs. 2021 Oct;39(5):1256-1266. doi: 10.1007/s10637-021-01118-1. Epub 2021 Apr 27. Invest New Drugs. 2021. PMID: 33905019
The anti-mesothelin monoclonal antibody amatuximab enhances the anti-tumor effect of gemcitabine against mesothelin-high expressing pancreatic cancer cells in a peritoneal metastasis mouse model.
Mizukami T, Kamachi H, Fujii Y, Matsuzawa F, Einama T, Kawamata F, Kobayashi N, Hatanaka Y, Taketomi A. Mizukami T, et al. Among authors: fujii y. Oncotarget. 2018 Sep 18;9(73):33844-33852. doi: 10.18632/oncotarget.26117. eCollection 2018 Sep 18. Oncotarget. 2018. PMID: 30333914 Free PMC article.
Multicentre cohort study of the impact of percutaneous coronary intervention on patients with concurrent cancer and ischaemic heart disease.
Nishikawa T, Morishima T, Okawa S, Fujii Y, Otsuka T, Kudo T, Fujita T, Kamada R, Yasui T, Shioyama W, Oka T, Tabuchi T, Fujita M, Miyashiro I. Nishikawa T, et al. Among authors: fujii y. BMC Cardiovasc Disord. 2021 Apr 13;21(1):177. doi: 10.1186/s12872-021-01968-w. BMC Cardiovasc Disord. 2021. PMID: 33849438 Free PMC article.
4,440 results